Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Ondas Inc. is now running a three-week pattern that reads more like a stress test than a stock: material corporate news, a Palantir joint venture, European aviation certification, a $56 million munitions order, absorbed without any meaningful short covering, and the stock down 9.4% on the week to $6.71.
The short book remains the defining feature of this name, and the data has barely shifted. Short interest eased fractionally on the week, down 1.4% to 63.8% of free float, from last week's 64.8%. That is still one of the most extreme short positions on Nasdaq. Availability has sat at 0% for every session in the data going back to early September, meaning every share in the lending pool is lent out, the tightest borrow market the stock has seen in the past year. New shorts cannot get in cheaply. Existing ones are not covering. The ORTEX short score of 71.7, in the second percentile of the full universe, captures that configuration precisely. What has changed is the cost to carry the position. Borrow costs have dropped from above 6.8% in early September to 3.49% now, down a further 12% on the week. That steady fall in carry burden is the most plausible explanation for why 64% of the float stays short despite a catalogue of positive announcements: holding is simply getting cheaper.
Options tell a different story from the short book. The put/call ratio has eased to 0.47, slightly below its 20-day average of 0.48 and near the lower end of the year's range. The z-score of negative 0.87 means options traders are not piling into protection. Relative to the scale of the short position, the options market looks almost relaxed, suggesting the bearish conviction is concentrated in the lending market rather than in derivatives.
The Street remains firmly bullish, in direct contrast to the short book. Three analysts carry buy-equivalent ratings and the mean price target sits at $18.88, implying more than 180% upside from current levels. Citizens initiated coverage on October 5 with a Market Outperform rating and a $14 target. Needham has maintained its Buy and $19 target through September. Ladenburg Thalmann and Oppenheimer both raised targets after the August earnings print. The bull case rests on an acquisition-driven platform now carrying roughly $757 million of backlog, with revenue projected to scale from $50.7 million in FY25 toward $1.5 billion by FY28. The bear case is equally straightforward: a share count that has grown more than six-fold since the start of FY25, around 195 million warrants outstanding, significant production exposure in Israel, and an execution timeline that depends on flawless integration of 19-plus acquisitions. EPS surprise ranks in the 96th percentile and analyst recommendation differential in the 98th, two of the highest factor scores in the universe. Short score rank sits at the second percentile, the inverse extreme. Few stocks carry that kind of simultaneous top-of-the-table bull signal and bottom-of-the-table bear signal.
Institutional ownership tells its own story about the share count expansion. BlackRock reported 39.5 million shares as of September 30, a position that increased by 30.2 million shares in the latest filing period. State Street added 9.2 million shares over the same period. Vanguard Capital Management added 4.4 million. These are passive index-driven flows rather than active conviction, almost certainly tracking the stock's growing float rather than making a directional call. One item on the 13D/G register is worth noting: Joseph V. Popolo, the sole activist Schedule 13D filer on record, filed an amendment in June 2025 showing his stake had dropped from 8.32% to 4.95%, falling below the 5% threshold. Stakes on the register are as last disclosed; a holder dropping below 5% may not file again. On the corporate register, retail attention has picked up materially. The ORTEX Wikipedia views signal is running at a z-score of 2.2 against the stock's own 90-day history, the highest retail attention reading in that window.
Insider activity is small in scale and routine in character. The CFO exercised and sold a net 4,952 shares in late September for just under $38,000. A director sold 7,500 shares in August under a pre-arranged 10b5-1 plan. There is no open-market buying from any insider in the past 90 days. Net insider flow over that period is negative $105,000. That is not a meaningful signal in either direction given the share count, but the absence of insider buying while the stock trades nearly 65% below the mean analyst target is a data point worth logging.
Earnings are due November 13. The last print produced a 5.4% fall on the day and a 14.2% decline over the following five days. The question heading into that date is whether the market is waiting for proof of integration and cash burn stabilisation, or whether the short book has already baked in a miss and carries less headline risk than the position size implies.
See the live data behind this article on ORTEX.
Open ONDS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
